Referred to the House Committee on Energy and Commerce.
The bill requires HHS, through the FDA Commissioner, to study availability, legal frameworks, and possible premarket approval requirements for preterm infant formula and to report to Congress within two years. For two years after enactment it preempts State or local requirements for preterm infant formula that differ from certain federal laws, with a narrow exception for civil or criminal actions against manufacturers for willful misconduct causing death or serious injury.
Progressives emphasize state accountability and consumer protections
Relative to its intended legislative type, this bill functions primarily as a substantive legal change (temporary federal preemption of state requirements concerning preterm infant formula) with a secondary reporting/study mandate; it is specific and detailed in its legal mechanics and integration with existing law but omits fiscal/resourcing language and fuller problem explication.
The bill requires HHS, through the FDA Commissioner, to study availability, legal frameworks, and possible premarket approval requirements for preterm infant formula and to report to Congress within two years.
For two years after enactment it preempts State or local requirements for preterm infant formula that differ from certain federal laws, with a narrow exception for civil or criminal actions against manufacturers for willful misconduct causing death or serious injury.
The bill allows removal of certain state suits to federal court, sets a clear-and-convincing burden for proving willful misconduct, and directs dismissal of pending actions to the extent they are preempted.
Narrow subject helps, but federal preemption, dismissal of suits, and burden-shifting raise political and coalition barriers; outcome depends on stakeholder support.
Relative to its intended legislative type, this bill functions primarily as a substantive legal change (temporary federal preemption of state requirements concerning preterm infant formula) with a secondary reporting/study mandate; it is specific and detailed in its legal mechanics and integration with existing law but omits fiscal/resourcing language and fuller problem explication.
Progressives emphasize state accountability and consumer protections
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize state accountability and consumer protections
Likely skeptical or concerned.
The study and potential FDA premarket approval could strengthen safety, but the two-year preemption and dismissal/removal of state suits raise accountability and public-health worries.
Cautiously receptive to federal study and harmonization, but wary of temporarily curtailing state authority and pending litigation.
Would favor safeguards ensuring rapid FDA action and preserved accountability.
Generally favorable.
Emphasizes uniform national rules, reduced litigation risk, and clearer federal standards.
Some caution about creating new federal premarket approval requirements is possible.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow subject helps, but federal preemption, dismissal of suits, and burden-shifting raise political and coalition barriers; outcome depends on stakeholder support.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize state accountability and consumer protections
Narrow subject helps, but federal preemption, dismissal of suits, and burden-shifting raise political and coalition barriers; outcome depen…
Relative to its intended legislative type, this bill functions primarily as a substantive legal change (temporary federal preemption of state requirements concerning preterm infant formula) with a secondary reporting/st…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.